• In January 2026, Arcutis Biotherapeutics released results from its nationwide Skin Insights survey, revealing how adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis view topical steroid use and disease management.
• The findings point to a widespread reliance on reactive, flare-focused care and high concern about steroid side effects, highlighting interest in longer-term, non-steroidal treatment approaches.
• We’ll now examine how this emphasis on unmet need for proactive, non-steroidal care could influence Arcutis Biotherapeutics’ broader investment narrative.

Rare earth metals are the new gold rush. Find out which 32 stocks are leading the charge.

What Is Arcutis Biotherapeutics' Investment Narrative?

For Arcutis, the big picture an investor needs to believe in is that a focused dermatology company can turn a growing ZORYVE franchise and pipeline into durable, profitable growth, despite its current losses and relatively full sales multiple. The Skin Insights survey fits into that story as more of a branding and market-shaping effort than a direct near term financial catalyst, reinforcing Arcutis’ positioning around chronic, non-steroidal, proactive care rather than immediately moving revenue or changing upcoming PDUFA and trial milestones. The key near term swing factors still look like execution on label expansions, physician uptake, and the upcoming Q4 2025 results, while the main risks center on Arcutis’ unprofitability, rich valuation relative to peers, and recent insider selling. The survey may slightly strengthen the longer term narrative, but is unlikely to be a material short term driver.

However, one emerging concern for investors is the recent pattern of insider selling. Arcutis Biotherapeutics' shares have been on the rise but are still potentially undervalued. Find out how large the opportunity might be.

Exploring Other Perspectives

Six Simply Wall St Community fair value estimates for Arcutis span roughly US$18 to above US$60, underlining how differently retail investors view its potential. Set that against the current reliance on successful ZORYVE execution and upcoming regulatory decisions, and it becomes clear why opinions split so sharply. You are seeing a real spread of views that rewards digging into several perspectives before deciding where you stand.

Explore 6 other fair value estimates on Arcutis Biotherapeutics - why the stock might be worth over 2x more than the current price!

Build Your Own Arcutis Biotherapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Arcutis Biotherapeutics research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Arcutis Biotherapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Arcutis Biotherapeutics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• Find companies with promising cash flow potential yet trading below their fair value.
• Uncover the next big thing with financially sound penny stocks that balance risk and reward.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.